Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20184042 | 0.90 | HDAC6 (0.51) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL20184029 | 0.90 | HDAC6 (0.53) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL20183987 | 0.89 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL20184007 | 0.88 | HDAC6 (0.53) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL20184059 | 0.86 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC5MAPK1 | |
| SCHEMBL20184017 | 0.86 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL20184056 | 0.85 | HDAC6 (0.47) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL20184060 | 0.85 | HDAC6 (0.49) | HDAC6HDAC1HDAC8HDAC5 | |
| SCHEMBL20184068 | 0.85 | HDAC6 (0.49) | HDAC6HDAC1HDAC8HDAC5HDAC4 | |
| SCHEMBL20184075 | 0.83 | HDAC4 (0.52) | HDAC6HDAC1HDAC8HDAC5HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357484-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-23 | — | — | US | disclosed |
| US-10357484-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-23 | — | — | US | disclosed |
| US-20190008836-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3327019-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3327019-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357484-B2 | Heterocyclic compound | HDAC1, HDAC11, HDAC5 | HDAC6 7/4885HDAC1 1/4885HDAC8 10/4885 |
| US-20190008836-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC11, HDAC5 | HDAC6 7/4885HDAC1 1/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.